Abstract：
BACKGROUND: The ideal dose of lasmiditan for migraine is not clear. This meta-analysis aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients.
METHODS: We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library Databases and selected the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model.
RESULTS: Five randomized controlled trials were included in this meta-analysis. Compared with lasmiditan 100-mg group in migraine patients, lasmiditan 200-mg group was associated with substantially increased pain free at 2 hours (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.12-1.44; P = 0.0002) and pain free at 24 hours (OR, 1.31; 95% CI, 1.08-1.60; P = 0.007) but demonstrated no obvious impact on pain relief at 2 hours (OR, 1.02; 95% CI, 0.91-1.16; P = 0.72) or MBS free at 2 hours (OR, 0.94; 95% CI, 0.77-1.14; P = 0.52). In addition, the incidence of adverse events was higher in lasmiditan 200-mg group than that in lasmiditan 100-mg group (OR, 1.29; 95% CI, 1.15-1.45; P < 0.0001).
CONCLUSIONS: Lasmiditan 200 mg is better for the treatment of migraine patients than lasmiditan 100 mg.
METHODS: We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library Databases and selected the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model.
RESULTS: Five randomized controlled trials were included in this meta-analysis. Compared with lasmiditan 100-mg group in migraine patients, lasmiditan 200-mg group was associated with substantially increased pain free at 2 hours (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.12-1.44; P = 0.0002) and pain free at 24 hours (OR, 1.31; 95% CI, 1.08-1.60; P = 0.007) but demonstrated no obvious impact on pain relief at 2 hours (OR, 1.02; 95% CI, 0.91-1.16; P = 0.72) or MBS free at 2 hours (OR, 0.94; 95% CI, 0.77-1.14; P = 0.52). In addition, the incidence of adverse events was higher in lasmiditan 200-mg group than that in lasmiditan 100-mg group (OR, 1.29; 95% CI, 1.15-1.45; P < 0.0001).
CONCLUSIONS: Lasmiditan 200 mg is better for the treatment of migraine patients than lasmiditan 100 mg.
摘要：
背景：治疗偏头痛的理想剂量尚不清楚。这项荟萃分析旨在比较200mg与100mg的lasmiditan对偏头痛患者的疗效。
方法：我们搜索了几个数据库，包括PubMed、Embase,WebofScience,EBSCO,和CochraneLibraryDatabases，并选择了随机对照试验，比较了200mg与100mglasmiditan对偏头痛患者的疗效。这项荟萃分析是使用随机效应模型进行的。
结果：本荟萃分析包括5项随机对照试验。与偏头痛患者的Lasmiditan100-mg组相比，Lasmiditan200-mg组与2小时无痛大幅增加相关(比值比[OR]，1.27；95%置信区间[CI]，1.12-1.44；P=0.0002）和24小时无痛（OR，1.31；95%CI，1.08-1.60；P=0.007），但在2小时对疼痛缓解无明显影响（OR，1.02；95%CI，0.91-1.16；P=0.72）或2小时无MBS（OR，0.94；95%CI，0.77-1.14；P=0.52）。此外,Lasmiditan200-mg组的不良事件发生率高于Lasmiditan100-mg组（OR，1.29；95%CI，1.15-1.45；P<0.0001）。
结论：Lasmiditan200mg治疗偏头痛患者优于Lasmiditan100mg。
方法：我们搜索了几个数据库，包括PubMed、Embase,WebofScience,EBSCO,和CochraneLibraryDatabases，并选择了随机对照试验，比较了200mg与100mglasmiditan对偏头痛患者的疗效。这项荟萃分析是使用随机效应模型进行的。
结果：本荟萃分析包括5项随机对照试验。与偏头痛患者的Lasmiditan100-mg组相比，Lasmiditan200-mg组与2小时无痛大幅增加相关(比值比[OR]，1.27；95%置信区间[CI]，1.12-1.44；P=0.0002）和24小时无痛（OR，1.31；95%CI，1.08-1.60；P=0.007），但在2小时对疼痛缓解无明显影响（OR，1.02；95%CI，0.91-1.16；P=0.72）或2小时无MBS（OR，0.94；95%CI，0.77-1.14；P=0.52）。此外,Lasmiditan200-mg组的不良事件发生率高于Lasmiditan100-mg组（OR，1.29；95%CI，1.15-1.45；P<0.0001）。
结论：Lasmiditan200mg治疗偏头痛患者优于Lasmiditan100mg。
